View Exam | PowerPak

1. Which of the following patients has a secondary immunodeficiency?

A. 7-month-old boy with severe combined immune deficiency regardless of IgG level B. 57-year-old woman with Hodgkin lymphoma and serum IgG level of 4.5 g/L C. 29-year-old woman with alcoholism and serum IgG level of 7.8 g/L D. 75-year-old man on phenytoin and with serum IgG level of 6.3 g/L

2. Among the medications that can cause secondary immunodeficiencies are those used in the treatment of which of the following diseases?

A. Cancers, autoimmune disorders, and endocarditis. B. Hyperthyroidism, inflammation, and autoimmune disorders. C. Autoimmune disorders, cancers, and inflammation. D. Inflammation, cancers, and endocarditis.

3. Which of the following is NOT a mechanism by which diseases or drugs cause secondary immunodeficiencies?

A. Decreases in eosinophil counts B. Decreases in neutrophil counts C. T cell depletion D. B cell depletion

4. The goal of therapy in treating adults with chronic idiopathic thrombocytopenia purpura with immunoglobulin G is:

A. Prevention of bacterial infections B. Prophylaxis against measles C. Prevention or control of bleeding D. Prevention of coronary artery aneurysms

5. Which of the following is NOT a correct pairing of IgG product and dosing consideration?

A. Cuvitru: Dosed every 4 weeks B. Gammagard: Available in 10% concentration C. Gamunex: Dosed every week D. Hizentra: Infused over 1 hour

6. An advantage of subcutaneous administration of immunoglobulin G over intravenous dosing is:

A. Higher peak and lower trough IgG levels B. Less patient education C. Less need for premedication D. Decreased frequency of administration

7. Which of the following products should NOT be used in patients for whom exposure to proline should be avoided?

A. Octagam B. Cuvitru C. Gamunex-C D. Privigen

8. Use of sugars as stabilizers in immunoglobulin G products is a safety concern in which of the following patients?

A. 7-month-old infant with a primary immunodeficiency B. 32-year-old man with diabetes C. 48-year-old woman with chronic liver disease D. 55-year-old woman with anti-IgA antibodies

9. Which of the following is the best dose for a 110-kg man who is 5 feet, 8 inches tall, if the product labeling calls for 1 g/kg for his condition?

A. 63.4 g B. 86.7 g C. 89.2 g D. 110 g

10. A patient is being converted from monthly intravenous immunoglobulin G to weekly subcutaneous Cuvitru. For a patient receiving an intravenous dose of 40 g monthly, what weekly dose should be administered subcutaneously?

A. 11 g B. 12 g C. 13 g D. 14 g

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following patients has a secondary immunodeficiency?

2. Among the medications that can cause secondary immunodeficiencies are those used in the treatment of which of the following diseases?

3. Which of the following is NOT a mechanism by which diseases or drugs cause secondary immunodeficiencies?

4. The goal of therapy in treating adults with chronic idiopathic thrombocytopenia purpura with immunoglobulin G is:

5. Which of the following is NOT a correct pairing of IgG product and dosing consideration?

6. An advantage of subcutaneous administration of immunoglobulin G over intravenous dosing is:

7. Which of the following products should NOT be used in patients for whom exposure to proline should be avoided?

8. Use of sugars as stabilizers in immunoglobulin G products is a safety concern in which of the following patients?

9. Which of the following is the best dose for a 110-kg man who is 5 feet, 8 inches tall, if the product labeling calls for 1 g/kg for his condition?

10. A patient is being converted from monthly intravenous immunoglobulin G to weekly subcutaneous Cuvitru. For a patient receiving an intravenous dose of 40 g monthly, what weekly dose should be administered subcutaneously?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following patients has a secondary immunodeficiency?

2. Among the medications that can cause secondary immunodeficiencies are those used in the treatment of which of the following diseases?

3. Which of the following is NOT a mechanism by which diseases or drugs cause secondary immunodeficiencies?

4. The goal of therapy in treating adults with chronic idiopathic thrombocytopenia purpura with immunoglobulin G is:

5. Which of the following is NOT a correct pairing of IgG product and dosing consideration?

6. An advantage of subcutaneous administration of immunoglobulin G over intravenous dosing is:

7. Which of the following products should NOT be used in patients for whom exposure to proline should be avoided?

8. Use of sugars as stabilizers in immunoglobulin G products is a safety concern in which of the following patients?

9. Which of the following is the best dose for a 110-kg man who is 5 feet, 8 inches tall, if the product labeling calls for 1 g/kg for his condition?

10. A patient is being converted from monthly intravenous immunoglobulin G to weekly subcutaneous Cuvitru. For a patient receiving an intravenous dose of 40 g monthly, what weekly dose should be administered subcutaneously?

« Return to Activity

Customers who Purchased
this Activity also Purchased